Saari W S, Wai J S, Fisher T E, Thomas C M, Hoffman J M, Rooney C S, Smith A M, Jones J H, Bamberger D L, Goldman M E
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486-0004.
J Med Chem. 1992 Oct 16;35(21):3792-802. doi: 10.1021/jm00099a007.
A series of nonnucleoside 3-aminopyridin-2(1H)-one derivatives was synthesized and evaluated for HIV-1 RT inhibitory properties. Several analogs proved to be potent and highly selective antagonists with in vitro IC50 values as low as 19 nM in the enzyme assay using rC.dG as template-primer. Two compounds from this series, 3-[[(4,7-dimethylbenzoxazol-2-yl)methyl]-amino]-5-ethyl-6-methy lpyridin-2(1H)-one (34, L-697,639) and the corresponding 4,7-dichloro analogue (37, L-697,661) inhibited the spread of HIV-1 IIIb infection by 95% in MT4 cell culture at concentrations of 25-50 nM and were selected for clinical trials as antiviral agents.